格隆汇9月30日丨上海谊众(688091.SH)公布，公司于近日取得交通银行股份有限公司上海奉贤支行出具 的《交通银行股票回购贷款承诺函》，贷款承诺额度不超过人民币3150万元（叁仟壹佰伍拾万元整）， 用于回购公司自身股票。 ...

证券之星消息，9月30日生物制品板块较上一交易日上涨0.49%，荣昌生物领涨。当日上证指数报收于 3882.78，上涨0.52%。深证成指报收于13526.51，上涨0.35%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688331 | 荣昌生物 | 116.88 | 6.25% | 8.59万 | 9.88.6 | | 688185 | 康布诺 | 79.52 | 2.59% | 1.68万 | + 1.33亿 | | 837344 | 三元基因 | 26.74 | 2.49% | 8498.98 | 2266.91万 | | 300357 | 我武生物 | 29.19 | 2.24% | 10.44万 | 3.05亿 | | 616889 | 欧林生物 | 27.20 | 1.95% | 5.92万 | 1.62亿 | | 301080 | 百普賽斯 | 59.56 | 1.79% | 2.01万 | 1.19亿 | | 430047 | 诺思兰德 | 2 ...

近日，江苏金迪克生物技术股份有限公司董事会收到副总经理宋斌的辞职报告。宋斌因个人原因申请辞 去副总经理职务，辞职后不再担任公司任何职务。其原定任期到2026年5月10日，实际离任时间为2025 年9月30日。宋斌已做好工作交接，辞职不会对公司生产经营造成不利影响，截至公告披露日，他未持 有公司股票，也无未履行的承诺事项。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 吴野，男，1975年6月出生，中共党员，无境外永久居留权，哈尔滨工业大学企业管理专业硕士研究 生，拥有深圳市创业投资从业人员专业资格。曾任南山基金管理有限公司财务经理，现任香港南海发展 有限公司财务负责人，兼深圳半岛城邦房地产有限公司及深圳半岛城邦置业有限公司财务副总经理。 2025年9月29日，公司第九届董事局第二十七次会议以9票同意、0票反对、0票弃权的表决结果，审议通 过了《关于召开2025年第二次临时股东会的议案》，决定于2025年10月24日以现场表决与网络投票相结 合的方式召开公司2025年第二次临时股东会。 3、会议召开的合法、合规性：本次股东会会议的召开符合上市公司相关法律、行政法规、部门规章、 规范性文件和《公司章程》的有关规定。 4、会议召开时间： 深圳市海王生物工程股份有限公司关于召开 2025年第二次临时股东会通知的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、召开会议基本情况 1、股东会届次：2025年第二次临时股东会 2、股东会召集人：深圳市海王生物工程股份有限公司董事局 ...

Core Viewpoint - The company reported a significant decline in revenue and profit for the first half of 2025, primarily due to a drop in sales of the shingles vaccine, which has been attributed to various factors affecting consumer demand and awareness [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 285 million yuan, a year-on-year decrease of 53.93% [1]. - The net profit for the same period was -73.57 million yuan, marking a shift from profit to loss compared to the previous year [1]. Vaccine Sales Analysis - The sales volume of the shingles vaccine during the reporting period was -17,300 doses, resulting in a sales revenue of -65.23 million yuan [1]. - The company sold 86,500 doses of the shingles vaccine at a price of 1,369 yuan per dose, generating approximately 115 million yuan in revenue [2]. - The company also conducted a welfare project, selling 43,900 doses at a discounted price (30-80% of the normal price), which contributed 29.49 million yuan to revenue [2]. Revenue Adjustments - Revenue was further impacted by returns of previously recognized sales, with 147,700 doses returned, leading to a revenue reduction of 196 million yuan [2]. - The company noted that factors such as low disease awareness and consumer willingness to receive the vaccine contributed to the decline in sales and revenue [1][2].

欧林生物9月29日大宗交易平台共发生3笔成交，合计成交量120.19万股，成交金额2558.40万元。以折溢 价进行统计，今日3笔大宗交易成交价相对收盘价均为折价交易。 进一步统计，近3个月内该股累计发生11笔大宗交易，合计成交金额为5535.07万元。 据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日，注册资本40593.36万人民 币。（数据宝） 证券时报·数据宝统计显示，欧林生物今日收盘价为26.68元，上涨4.63%，日换手率为1.62%，成交额为 1.74亿元，全天主力资金净流出427.42万元，近5日该股累计下跌2.56%，近5日资金合计净流入119.35万 元。 两融数据显示，该股最新融资余额为3.11亿元，近5日减少1933.07万元，降幅为5.85%。 | 成交量 （万 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 45.00 | 1017.00 | 22 ...

每经头条（nbdtoutiao）——农夫大战怡宝，抢到更多蛋糕的却是宗馥莉！农夫绿瓶上市后，怡宝上 演"滑铁卢"：市占率大跌近5个百分点 （记者 王晓波） 2025年1至6月份，天坛生物的营业收入构成为：生物制品行业占比99.68%，其他业务占比0.32%。 截至发稿，天坛生物市值为380亿元。 每经AI快讯，天坛生物（SH 600161，收盘价：19.2元）9月29日晚间发布公告称，公司董事会于近日收 到公司总法律顾问、首席合规官慈翔女士递交的书面辞职报告，慈翔女士辞去总法律顾问、首席合规官 职务，慈翔女士的辞职报告自送达公司董事会之日起生效。 因慈翔女士离任后，公司控股子公司国药集团西安生物制药有限公司董事会成员低于法定人数，慈翔女 士将继续履行天坛西安董事职责，期限至天坛西安选举新任董事之日止。 ...

证券之星消息，9月29日生物制品板块较上一交易日上涨0.78%，诺思兰德领涨。当日上证指数报收于 3862.53，上涨0.9%。深证成指报收于13479.43，上涨2.05%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300841 | 康华生物 | 75.47 | -2.34% | 4.08万 | 3.07亿 | | 301080 | 百普赛斯 | 58.51 | -2.32% | 2.00万 | · 1.17亿 | | 688443 | 智规全泰 | 30.90 | -2.22% | 5.54万 | 1.72亿 | | 603087 | 日李药业 | 76.37 | -2.18% | 1 20.74万 | 15.73亿 | | 002581 | ST未名 | 7.93 | -1.98% | 4.98万 | 3952.68万 | | 000534 | 万泽股份 | 15.22 | -1.30% | 6.89万 | 1.05亿 | | 000403 | 派林生物 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.2% from September 22 to September 26, underperforming compared to the Wind All A index (0.25%) and the CSI 300 index (1.07%) [3][8] - The flu season is becoming active, with monitoring data indicating a slow upward trend in respiratory infectious diseases, particularly in southern provinces [3][12] - The upcoming ESMO conference from October 17 to 21 in Berlin will feature significant research contributions from Chinese scholars, with 23 studies included in the Late-Breaking Abstracts [3][12] Market Weekly Review - The pharmaceutical and biotechnology sector declined by 2.2%, with only the other biological products sector showing a slight increase of 0.05%. The raw materials sector saw a significant drop of 8.22% [8][9] - Notable stock performances included Sunflower (57.9% increase), Aopumai (23.9% increase), and Xinlitai (15.8% increase), while Borui Pharmaceutical (-38.4%) and Zhongsheng Pharmaceutical (-14%) faced significant declines [11][12] Industry News and Key Company Announcements - The National Healthcare Security Administration launched a "100-day action" to address prominent issues in medical insurance fund management, effective until December 31, 2025 [12][13] - Pfizer announced its acquisition of Metsera for approximately $4.9 billion, focusing on developing next-generation obesity and cardiometabolic disease drugs [16][17] - The ESMO conference has highlighted 23 groundbreaking studies from Chinese researchers, marking a significant achievement for the industry [16][17]

Traditional Dividend Assets - White appliances' cash flow ratio decreased to 26% in Q2 2025, primarily due to increased allocation of financial assets impacting cash flow space[11] - The cash flow ratio for liquor reached 55% in Q2 2025, with a reduction in the allocation of financial assets compared to previous quarters[19] Cash Flow Improvement Assets - Black appliances' cash flow ratio was 24% in Q2 2025, with capital expenditure reduced to a historical low of 0.7, indicating a potential shift to a new high expenditure cycle[24] - Lighting equipment's cash flow ratio improved to 31% in Q2 2025, as financial asset allocation decreased, allowing cash flow to return to positive[33] - Beauty care's cash flow ratio was 47% in Q2 2025, driven by reduced capital expenditure, which fell to a historical low of 1.4[39] Stable Cash Flow Assets - Textile manufacturing maintained a cash flow ratio of 21% in Q2 2025, with stable cash flow generation since 2022[47] - The apparel and home textile sector achieved a cash flow ratio of 52% in Q2 2025, entering a phase of stable cash flow generation due to reduced capital expenditure[51] Assets Under Pressure - Traditional Chinese medicine and beverage sectors are under pressure, with profitability not showing signs of improvement, particularly in the context of centralized procurement affecting traditional Chinese medicine[3] - The non-liquor beverage sector, including beer and wine, continues to face challenges, with profitability remaining under pressure[3]